🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the battle against increasingly resistant strains of the bacteria, according to health experts.

A Worldwide Public Health Issue

Cases of gonorrhoea are escalating worldwide, with data suggesting in excess of 82 million infections per year. Notably increased rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune development in the face of growing infection rates, increasing antimicrobial resistance and the very limited treatment choices presently on offer.”

Medical experts are increasingly worried about the surge in drug-resistant strains. The global health body has classified it as a "high-priority threat". Recent surveillance found that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Therapies Gain Approval

Zoliflodacin, also known as Nuzolvence, was cleared by the American regulatory agency in December for treating gonorrhoea. This infection can lead to major issues, including infertility. Researchers hope that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, created by the pharmaceutical company GSK, also received approval in the same week. This treatment, which is also used to treat urinary tract infections, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to see it through.

“This approval represents a significant shift in the therapy of superbug gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Clinical Trial Data and Worldwide Availability

According to results detailed in a prominent scientific publication, the new drug eradicated the vast majority of uncomplicated infections. This puts it on an comparable level with the existing first-line therapy, which involves two antibiotics. The research included hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the ability to register and commercialise the drug in numerous low-income and middle-income countries.

Medical professionals treating patients have expressed positive views. Access to a easy-to-administer therapy such as this is hailed as a "game-changer" for public health efforts. This is considered crucial to alleviate the strain of the illness for people and to prevent the spread of extremely resistant gonorrhoea globally.